Amgen (AMGN) – Analysts’ Weekly Ratings Changes

Amgen (NASDAQ: AMGN) recently received a number of ratings updates from brokerages and research firms:

• 9/17/2026 – Amgen had its “buy” rating reaffirmed by UBS Group AG. They now have a $430.00 price target on the stock.
• 9/10/2026 – Amgen was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $425.00 price target on the stock, down from $445.00.
• 9/8/2026 – Amgen was downgraded by BMO Capital Markets from “outperform” to “market perform”. They now have a $450.00 price target on the stock.
• 9/8/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $400.00 price target on the stock.
• 9/4/2026 – Amgen had its price target raised by Wells Fargo & Company from $400.00 to $435.00. They now have an “equal weight” rating on the stock.
• 8/20/2026 – Amgen had its price target raised by Piper Sandler from $427.00 to $457.00. They now have an “overweight” rating on the stock.
• 8/19/2026 – Amgen had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $362.00 price target on the stock.
• 8/19/2026 – Amgen had its price target raised by Argus from $375.00 to $460.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Amgen had its price target raised by Cantor Fitzgerald from $350.00 to $400.00. They now have a “neutral” rating on the stock.
• 8/18/2026 – Amgen had its price target raised by Mizuho from $303.00 to $352.00. They now have a “neutral” rating on the stock.
• 8/14/2026 – Amgen had its price target raised by Barclays PLC from $360.00 to $380.00. They now have an “equal weight” rating on the stock.
• 8/10/2026 – Amgen had its price target raised by Guggenheim from $343.00 to $388.00. They now have a “neutral” rating on the stock.
• 8/8/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Amgen had its price target raised by Citigroup Inc. from $345.00 to $405.00. They now have a “neutral” rating on the stock.
• 8/6/2026 – Amgen was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/6/2026 – Amgen had its price target raised by Sanford C. Bernstein from $335.00 to $345.00. They now have a “market perform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by UBS Group AG from $420.00 to $440.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by TD Cowen from $420.00 to $452.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have a “sector outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Truist Financial Corporation from $340.00 to $362.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Oppenheimer Holdings, Inc. from $400.00 to $450.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Morgan Stanley from $333.00 to $351.00. They now have an “equal weight” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Royal Bank Of Canada from $370.00 to $400.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Robert W. Baird from $215.00 to $230.00. They now have an “underperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Bank of America Corporation from $312.00 to $317.00. They now have an “underperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Canaccord Genuity Group Inc. from $366.00 to $384.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Wells Fargo & Company from $390.00 to $400.00. They now have an “equal weight” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by BMO Capital Markets from $400.00 to $450.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – Amgen had its price target raised by Barclays PLC from $350.00 to $360.00. They now have an “equal weight” rating on the stock.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.